329 related articles for article (PubMed ID: 31201616)
1. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
3. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
4. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
5. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
[TBL] [Abstract][Full Text] [Related]
6. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
7. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
8. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.
McBride A; Alrawashdh N; MacDonald K; Abraham I
Future Oncol; 2022 Jan; 18(3):363-373. PubMed ID: 34747185
[TBL] [Abstract][Full Text] [Related]
9. [Trastuzumab and its biosimilars].
Sarosiek T; Morawski P
Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
[TBL] [Abstract][Full Text] [Related]
10. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
Hara F; Tajima K; Tanabe K
Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
Esteva FJ; Saeki T; Kim H; Stebbing J
Future Oncol; 2018 Aug; 14(19):1909-1919. PubMed ID: 29482364
[TBL] [Abstract][Full Text] [Related]
12. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.
Brodszky V; Rencz F; Péntek M; Baji P; Lakatos PL; Gulácsi L
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):119-25. PubMed ID: 26162458
[TBL] [Abstract][Full Text] [Related]
13. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
14. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.
Brodszky V; Baji P; Balogh O; Péntek M
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S65-71. PubMed ID: 24832837
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of CT-P6 in HER2 positive breast cancer.
Fu C; Stebbing J; Esteva FJ
Expert Opin Biol Ther; 2019 Oct; 19(10):987-992. PubMed ID: 31507219
[No Abstract] [Full Text] [Related]
16. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
Giuliani J; Bonetti A
Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
[TBL] [Abstract][Full Text] [Related]
17. Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study.
Saito Y; Tamaki S; Hasegawa H; Takahashi K; Tokutome A; Takekuma Y; Yamashita H; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(4):474-477. PubMed ID: 33790098
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
